Ethical Issues in Biotechnology — Revision Notes

⚡ 30-Second Revision

Article 21: Right to Life, includes genetic privacy & consent.
Article 47: State's duty to improve public health, justifies biotech use.
Genetic Engineering: 'Designer babies,' dual-use, equitable access.
Stem Cells: Embryonic (controversial) vs. Adult (less controversial); Therapeutic vs. Reproductive cloning.
CRISPR-Cas9: Precision, off-target effects, germline editing (He Jiankui).
Biopiracy: Exploitation of traditional knowledge (TK), addressed by Biological Diversity Act 2002 & Nagoya Protocol.
GMOs: Food security vs. environment, corporate control (Bt cotton, Golden Rice).
Patents: TRIPS, Doha Declaration, compulsory licensing (COVID-19 vaccines).
Reproductive Cloning: Universally prohibited (Dolly the sheep).
Germline Gene Therapy: Prohibited due to heritable changes.

2-Minute Revision

Ethical issues in biotechnology are central to UPSC, spanning GS-3 and GS-4. Key areas include genetic engineering, raising concerns about 'designer babies,' dual-use potential, and equitable access to advanced therapies.

Stem cell research debates the moral status of embryos (embryonic vs. adult stem cells) and the clear distinction between therapeutic and reproductive cloning, with the latter being globally prohibited.

CRISPR-Cas9 technology, while revolutionary, intensifies these debates, particularly concerning human germline editing and its irreversible, heritable changes, exemplified by the He Jiankui case. In agriculture, Genetically Modified Organisms (GMOs) like Bt cotton and Golden Rice present ethical dilemmas balancing food security with environmental impact, corporate control, and farmer welfare.

Biopiracy, the unauthorized use of traditional knowledge and genetic resources, is addressed by India's Biological Diversity Act 2002 and international frameworks like the Nagoya Protocol. Finally, biotechnology patents raise critical questions about access to essential medicines, as seen in the COVID-19 vaccine patent waiver discussions, guided by the TRIPS Agreement and the Doha Declaration.

India's constitutional articles (21, 47) and specific guidelines (ICMR-DBT) provide the ethical and legal framework for navigating these complex issues, emphasizing responsible innovation and public welfare.

5-Minute Revision

Biotechnology's rapid advancements necessitate a robust ethical framework, a key area for UPSC. The core ethical issues revolve around human dignity, justice, safety, and environmental impact. Genetic engineering, including gene therapy and CRISPR-Cas9, presents dilemmas such as the potential for 'designer babies,' the irreversibility of germline modifications, and the dual-use nature of the technology.

Informed consent and equitable access are paramount, especially given the high costs of advanced therapies. The He Jiankui case starkly illustrated the dangers of unregulated germline editing.

Stem cell research is ethically divided, with embryonic stem cells (ESCs) sparking debates over embryo destruction, while adult stem cells (ASCs) are less controversial. Therapeutic cloning, aimed at generating patient-specific cells, is distinct from reproductive cloning, which is universally condemned for its implications on human individuality and dignity, as highlighted by Dolly the sheep's cloning.

In agriculture, GMOs like Bt cotton and Golden Rice involve ethical considerations of food security, environmental impact (gene flow, pest resistance), corporate control over seeds, and farmer welfare. Biopiracy, the exploitation of traditional knowledge and genetic resources, is a major concern for India, addressed by the Biological Diversity Act 2002 and international agreements like the Nagoya Protocol, which aim for fair and equitable benefit sharing.

Intellectual property rights in biotechnology, particularly patenting, raise moral questions about access to essential medicines. The TRIPS Agreement and the Doha Declaration provide a framework for balancing innovation incentives with public health needs, as seen in the COVID-19 vaccine patent waiver debates.

India's constitutional provisions (Article 21 for privacy and consent, Article 47 for public health) and specific guidelines (e.g., ICMR-DBT for stem cells) form the bedrock of its ethical and regulatory approach, aiming to foster responsible innovation while safeguarding societal values and human rights.

Understanding these interconnected issues and their legal-policy dimensions is crucial for comprehensive UPSC preparation.

Prelims Revision Notes

For Prelims, focus on specific terms, definitions, and their direct associations.

Genetic Engineering: — Manipulation of genes. Ethical concerns: 'designer babies,' dual-use (beneficial/harmful), equitable access, informed consent.
Gene Therapy: — Somatic (non-heritable, less controversial) vs. Germline (heritable, highly controversial, generally prohibited).
CRISPR-Cas9: — Gene-editing tool. Known for precision but also off-target effects. He Jiankui case: first germline-edited babies, widely condemned.
Stem Cells: — Embryonic (pluripotent, from embryos, ethically contentious) vs. Adult (multipotent, from adult tissues, less contentious).
Cloning: — Therapeutic (for research/therapy, embryo destroyed, regulated) vs. Reproductive (to create identical organism, prohibited, e.g., Dolly the sheep).
GMOs: — Genetically Modified Organisms. Ethical debates: food security, environmental impact (gene flow), corporate control (Bt cotton, Golden Rice).
Biopiracy: — Unauthorized use of traditional knowledge (TK) and genetic resources. Addressed by Biological Diversity Act 2002 (India) and Nagoya Protocol (international).
Patents: — Biotechnology patents raise issues of access to medicines. TRIPS Agreement (WTO) sets IPR standards. Doha Declaration (2001) allows flexibilities for public health (e.g., compulsory licensing). COVID-19 vaccine patent waiver debates.
Constitutional Basis: — Article 21 (Right to Life, privacy, bodily integrity), Article 47 (State's duty to public health).
Key Indian Regulations: — Biological Diversity Act 2002, Patents Act 1970 (Section 3(j) on non-patentability of life forms), ICMR-DBT Guidelines for Stem Cell Research 2017 (prohibits reproductive cloning, germline therapy).
International Frameworks: — UNESCO Universal Declaration on Human Genome and Human Rights (human dignity), Cartagena Protocol on Biosafety (LMOs, transboundary movement).

Mains Revision Notes

For Mains, develop an analytical framework that connects ethical principles, technological advancements, and policy implications.

Framework for Analysis: — Always consider the principles of Autonomy (informed consent, genetic privacy), Beneficence (potential benefits to health/agriculture), Non-maleficence (potential harms, unforeseen consequences), Justice (equitable access, avoiding discrimination, benefit sharing), and Human Dignity.
Genetic Engineering & Gene Therapy: — Discuss the promise (disease cure) vs. peril ('designer babies,' germline alteration). Emphasize the need for robust ethical oversight and public dialogue. Connect to Article 21 for individual rights.
CRISPR: — Analyze its transformative power and the intensified ethical debates it brings, especially for germline editing. Discuss the regulatory lag and the need for global consensus.
Stem Cells & Cloning: — Focus on the moral status of the embryo. Differentiate therapeutic vs. reproductive cloning, highlighting why one is regulated and the other prohibited. Refer to ICMR-DBT guidelines.
GMOs: — Frame the debate around food security vs. environmental/socio-economic risks. Use Bt cotton and Golden Rice as case studies to illustrate corporate control, farmer welfare, and public acceptance issues. Connect to Article 47 for public health/nutrition.
Biopiracy & IPR: — Analyze the conflict between Western IPR systems and traditional knowledge. Discuss the role of the Biological Diversity Act and Nagoya Protocol in ensuring fair benefit sharing. Emphasize India's stance.
Policy & Governance: — Stress the need for adaptive, multi-stakeholder governance. Discuss the role of national strategies, regulatory bodies, and international cooperation in navigating ethical challenges. Highlight the flexibilities in TRIPS (Doha Declaration) for public health.
Vyyuha Analysis: — Remember the Indian context – balancing developmental needs with ethical caution, protecting traditional knowledge, and ensuring equitable access amidst socio-economic disparities. This provides a unique angle for your answers.

Vyyuha Quick Recall

GENETIC: Germline editing (controversial, heritable) Equitable access (cost, disparity) Non-maleficence (do no harm, safety) Embryo status (stem cells, cloning) Traditional knowledge (biopiracy, IPR) Informed consent (autonomy, privacy) Corporate control (GMOs, patents)